Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Zenabis Global Inc. T.ZENA

We are a diverse, passionate team of doctors, scientists, researchers, growers, educators, and advocates who came together with the goal of increasing access to safe, high quality cannabis for medical patients and recreational consumers. Our four facilities are located coast-to-coast across Canada in Delta and Langley, British Columbia; Atholville, New Brunswick; and Stellarton, Nova Scotia. Zenabis currently owns 3.5 million square feet of facility space.


TSX:ZENA - Post by User

Comment by Jimmy713on May 15, 2021 11:37am
103 Views
Post# 33209895

RE:ZENA Q1/2021

RE:ZENA Q1/2021We should get another offer next week, and it should get matched by Hexo too...
Dreamy Bussiness Partners Keep Fingers Crossed, Believe In Good Luc Stock Photo - Image of friend, pensioner: 132847894

Jimmy713 wrote:
Zenabis Announces First Quarter 2021 Financial Results

Canada NewsWire

VANCOUVER, BC May 14, 2021 /CNW/ - Zenabis Global Inc. (TSX: ZENA) (" Zenabis " or the " Company ") today announced its financial results for the quarter ended March 31, 2021 . All amounts, unless specified otherwise, are expressed in Canadian dollars.

First Quarter 2021 Highlighted Financial Results

  • Quantity of cannabis sold totaled 4,753 kg in Q1 2021, which was 27% greater compared to 3,730 kg in Q1 2020;
  • Consolidated gross revenue totaled $16.2 million in Q1 2021, 8% higher than $15.0 million in q1 2020;
  • Gross margin before fair value changes to biological assets and inventories was $2.7 million or 21.5% of net revenue in Q1 2021, compared to $5.0 million or 39.7% of net revenue in Q1 of the prior year;
  • Consolidated Adjusted EBITDA for the quarter totaled a loss of $1.9 million , compared to loss of $768 thousand in Q1 2020;
  • Consolidated net income for the quarter totaled $9.1 million or $0.01 per share, fully diluted, compared to a loss of $7.8 million or $0.02 per share, fully diluted, in the same quarter of last year;



<< Previous
Bullboard Posts
Next >>